Literature DB >> 15929083

Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action.

Venkata S Sabbisetti1, Srinivasulu Chirugupati, Shibu Thomas, Kedar S Vaidya, Dean Reardon, Maurizio Chiriva-Internati, Kenneth A Iczkowski, Girish V Shah.   

Abstract

Calcitonin (CT) is synthesized and secreted in prostate epithelium, and its secretion from malignant prostates is several-fold higher than from benign prostates. CT receptor (CTR) is expressed in malignant prostate epithelium, and its activation stimulates growth of prostate cancer (PC) cells via activation of adenylyl cyclase and calcium/phospholipid pathways. To identify the role of "CT System" in prostate cancer, we tested the expression of CT and CTR mRNAs in invading tumor cells of prostate cancer specimens. The effect of CT on in vitro invasion of PC cell lines and on activation of gelatinases was also examined. The cells of primary tumors and those invading stroma co-expressed CT/CTR mRNAs. Exogenously added CT increased in vitro invasion of PC cell lines and caused a rapid, several-fold but transient increase in protein kinase A activity. In contrast, anti-CT serum caused a dose-dependent inhibition of in vitro invasion of PC-3M cells. CT also increased the concentration and activities of MMP-2 and MMP-9. Rp.cAMP, a competitive inhibitor of cAMP-dependent protein kinase A, myristoylated protein kinase A inhibitory peptide (PKI) as well as the expression of dominant negative form of PKA all attenuated basal in vitro invasion of PC-3M cells, and CT could not increase in vitro invasiveness in their presence. These results suggest that overexpression of "CT System" in invasive PC tumors significantly contributes to increased invasiveness of prostate cancer cells. The action of CT may be mediated by protein kinase A signaling, which subsequently leads to increased cell invasion and secretion of gelatinases. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15929083     DOI: 10.1002/ijc.21158

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  A-kinase anchoring protein 2 is required for calcitonin-mediated invasion of cancer cells.

Authors:  Arvind Thakkar; Ahmed Aljameeli; Shibu Thomas; Girish V Shah
Journal:  Endocr Relat Cancer       Date:  2015-10-02       Impact factor: 5.678

Review 2.  Immunotherapy in prostate cancer: emerging strategies against a formidable foe.

Authors:  Marijo Bilusic; Christopher Heery; Ravi A Madan
Journal:  Vaccine       Date:  2011-07-07       Impact factor: 3.641

3.  Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis.

Authors:  Girish V Shah; Anbalagan Muralidharan; Shibu Thomas; Mitan Gokulgandhi; Mudit Mudit; Mohammad Khanfar; Khalid El Sayed
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

4.  Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling.

Authors:  Shibu Thomas; Maurizio Chiriva-Internati; Girish V Shah
Journal:  Clin Exp Metastasis       Date:  2007-05-09       Impact factor: 5.150

5.  Elevating SOX2 in prostate tumor cells upregulates expression of neuroendocrine genes, but does not reduce the inhibitory effects of enzalutamide.

Authors:  Ethan P Metz; Phillip J Wilder; Jixin Dong; Kaustubh Datta; Angie Rizzino
Journal:  J Cell Physiol       Date:  2019-10-06       Impact factor: 6.384

6.  Cadherin switching and activation of beta-catenin signaling underlie proinvasive actions of calcitonin-calcitonin receptor axis in prostate cancer.

Authors:  Girish V Shah; Anbalagan Muralidharan; Mitan Gokulgandhi; Kamal Soan; Shibu Thomas
Journal:  J Biol Chem       Date:  2008-11-09       Impact factor: 5.157

7.  Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion.

Authors:  Andrew J McKenzie; Shirley L Campbell; Alan K Howe
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

8.  Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer.

Authors:  Ilaria Bellezza; Hannes Neuwirt; Constanze Nemes; Ilaria T Cavarretta; Martin Puhr; Hannes Steiner; Alba Minelli; Georg Bartsch; Felix Offner; Alfred Hobisch; Wolfgang Doppler; Zoran Culig
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

9.  MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells.

Authors:  Eric W Robbins; Emily A Travanty; Kui Yang; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2008-09-15       Impact factor: 4.430

Review 10.  Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.

Authors:  Harm Westdorp; Annette E Sköld; Berit A Snijer; Sebastian Franik; Sasja F Mulder; Pierre P Major; Ronan Foley; Winald R Gerritsen; I Jolanda M de Vries
Journal:  Front Immunol       Date:  2014-05-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.